CorrectSequence Therapeutics to Participate in the 27th Annual Meeting of American Society of Gene & Cell Therapy

2024-04-13 09:00:00 Correctseq 644

April 13, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announced an oral presentation and 3 poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Dr. Peixue(Jason) Li, Head of Translational Science of Correctseq will participate in this conference and give an oral presentation titled “Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)on May 9, at 2:15 pm - 2:30 pm, EST.

 

Session Title: Correction of Genetic Disorders of the Blood and Immune System

Session Date/Time: Thursday May 9, 2024 1:30 PM-3:15 PM, EST

Presentation Title: Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)

Speaker: Peixue(Jason) Li, Ph.D., Head of Translational Science, Correctseq

Presentation Time: 2:15 PM-2:30 PM, EST

Room: 314-317

Abstract Number: 173

Format: Oral presentation

 

Session Title: Wednesday Posters: Base Editing and Prime Editing

Session Date/Time: Wednesday May 8, 2024 12:00 PM, EST

Poster Title: Innovative Transformer Base Editor (tBE)-Mediated Undetected Off-Target Base Editing and Its Potential Clinical Applications for Unmet Medical Needs

Presentation Room: Exhibit Hall

Abstract Number: 688

Format: Poster

 

Session Title: Wednesday Posters: Metabolic Diseases

Session Date/Time: Wednesday May 8, 2024 12:00 PM, EST

Poster Title: Precise Base Editing of Hyperlipidemia-Associated Genes by the Transformer Base Editor to Reduce Blood Lipid Levels

Presentation Room: Exhibit Hall

Abstract Number: 585

Format: Poster

 

Session Title: Thursday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies

Session Date/Time: Thursday May 9, 2024 12:00 PM, EST

Poster Title: Efficient Genome Editing of Human T Cells with Innovative Transformer Base Editor (tBE) for Construction of Next Generation CAR-T Therapies

Presentation Room: Exhibit Hall

Abstract Number: 1315

Format: Poster

 

For more information about the meeting, visit: https://annualmeeting.asgct.org/  

 

About CorrectSequence Therapeutics

CorrectSequence TherapeuticsTM (CorrectseqTM) (www.correctsequence.com) is a clinical stage biotechnology company aims to use our innovative gene editing technology to help people with severe diseases. We have developed multiple base editing systems and the transformer Base Editing (tBE) system with the best safety and efficacy performance is currently applied in all the IND enabling pipelines. Multiple pipelines for genetic diseases, cancer immunotherapy, metabolic diseases, infectious diseases are well underway. We are also working on novel target screening for tBE editing in ophthalmology and neurological diseases. We focus on biotechnology innovation, research and development and are committed to providing efficient, reliable and safe solution for unmet medical needs.

 

 


CorrectSequence Therapeutics Co., Ltd. © (2021-2022)
沪ICP备2020032248号
Powered by MetInfo 7.7 ©2008-2024  mituo.cn
HOME
ABOUT
NEWS
CONTACT